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Surgery to restore blood flow in arteries blocked by atherosclerotic plaque is a common treatment in cardiovascular disease. Long-
term complications of surgical treatment are vein graft disease and restenosis, a renarrowing of the blood vessel after bypass
or removal of the culprit atherosclerotic plaque. Attempts to prevent or treat these complications by systemic pharmacological
approaches have been largely unsuccessful in the clinic. This has led to an interest in developing targeted or locally delivered
strategies. This paper discusses many of the various site-delivered therapies that are under examination as potential antirestenotic
and antivein graft disease agents (including antithrombotic, antiproliferative, and anti-inflammatory agents) and why many
therapies developed in animal models fail in clinical trials. Techniques of targeted delivery (including stents, “magic bullets,” and
adventitial delivery) and delivery systems (including nanoparticles and the use of gene therapy) are also discussed.
1. Introduction
Cardiovascular disease is the leading cause of death and
disease globally, with over 17 million people dying of
cardiovascular disease each year. Seventy-five percent of these
deaths are due to acute events, such as myocardial infarction
or stroke, which are commonly caused by blockage of culprit
arteries by atherosclerotic plaques [1].
While pharmacological treatments are used to control
vascular disease progression or symptoms in patients with
mild disease, surgery may be required in more severe or
acute cases [2, 3]. Surgical therapies to treat atherosclerosis
target the stenosing atherosclerotic lesion, to restore the flow
of blood to downstream organs and tissues. These surgical
treatments include arterial bypass grafting (coronary and
peripheral bypass grafting), endarterectomy, and angioplasty
(with or without stent placement). Although these proce-
dures have improved both patient mortality and quality of
life, their success is limited by immediate occlusive compli-
cations in up to 18% of patients, and by the longer-term
complications of vein graft disease (vein graft thickening)
or restenosis (arterial reblockage at the same site), often
resulting in partial or complete closure of surgically treated
vessels by 10 years after the procedure [2, 4–8].
Neointimal formation is central to both vein graft failure
and restenosis [9–12], and also contributes to blockages
in arteriovenous shunts and transplanted organs. The
neointima is predominantly formed of smooth muscle cells
(SMCs) and extracellular matrix, but other components,
such as inflammatory cells and thrombus remnants, may
also be present [13–16]. Many approaches have been
explored to prevent neointimal formation and associated
pathological sequelae. These strategies include pharmaco-
logical (e.g., cytostatic drugs, anti-inflammatory agents),
mechanical (sheaths, internal stents), genetic (gene transfer,
stem/progenitor cells), and combination therapies (drug-
eluting stents, antibody-directed treatments, nanoparticle-
based platforms) [10, 17, 18], but the complete therapeutic
prevention of neointimal formation is yet to be achieved.
Many agents used systemically have been eﬀective in
preventing restenosis or vein graft disease in animal models
have not successfully translated into clinical practice for a
number of reasons, including lack of patient compliance,
deleterious side eﬀects or diﬃculties in establishing dosing
regimens [19–21]. The antirestenotic drug needs to be
present at the site of injury both immediately after surgery
and for suﬃcient time after that, to cover the “window of
opportunity.” If insuﬃcient drug is given, or given too late,
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for a too short time, or intermittently, then restenosis may
still occur. Targeted (or local) treatment not only reduces the
amount of drug required (compared with systemic admin-
istration), it also eliminates the need for repeated dosing
and minimises side eﬀects. One form of local treatment is
the drug-eluting stent, which has reduced the restenosis rate
to less than 10% [3, 7, 22, 23]. However, it is not possible
to use stents to treat all atherosclerotic plaques, and there
are concerns regarding stent cost and safety. There are also
problems when incomplete stent apposition or inflammation
occurs, but of more concern are complications due to
delayed or incomplete reendothelialization and/or abnormal
endothelial function, leading to late stent thrombosis (and
delayed mortality) [24, 25]. However, drug-eluting stents are
not the only local treatments available; there are alternative,
low-cost, targeted delivery systems.
1.1. Management Strategies for Atherosclerosis. Pharmacolog-
ical treatments adequately control mild disease progression
or symptoms in patients with mild disease [2]. When the
coronary or peripheral arteries are extensively damaged or
blocked for long stretches, the blocked area may be bypassed
by inserting an alternate conduit for the passage of the
blood, the bypass graft. The vessels of first choice for such
a procedure are the patient’s own arteries. If these are
unavailable, then autologous veins (usually saphenous vein)
or bioartificial or synthetic grafts may be used. Vascular
SMCs can respond to environmental changes, by changing
from a contractile phenotype to a synthetic phenotype, with
more organelles associated with synthesis and proliferation
[26, 27] and increased production of proteases (such as
heparanase, matrix metalloproteinases, and cathepsins) to
remodel their surrounding extracellularmatrix [28–30]. Vein
preparation prior to implantation results in a basal cell death
rate of 3%, with more “synthetic” SMC and an increase
in degradative enzymic activity [28, 30]. Gross damage in
the vein also occurs once the graft is suddenly exposed to
arterial (high-pressure) flow. The endothelium is sloughed
away and individual cells are damaged. Underlying SMCs
accumulate fluid, and matrix proteins in the adventitia are
fractured and the vasa vasorum (if any remains) thromboses
[31]. Reperfusion injury factors (such as superoxide radical
formation) are observed [32, 33], so that the vein shows
the influence of both preimplant injury and the new high-
pressure environment.
While open surgery, such as bypass grafting, remains
popular, this technique has several diﬃculties: (a) the patient
is exposed to general anaesthesia and all the problems
associated with that procedure; (b) the stenosing lesion may
be in a position inaccessible to direct surgery; or (c) the
stenosing area may consist of multiple or diﬀuse lesions that
cannot easily be removed [34]. Several techniques that do
not require the patient to undergo a general anaesthetic have
been developed to remove the oﬀending lesion and may
indeed be performed in a day clinic. These include crushing
the lesion with a dilating balloon, removal of the lesion
with rotating knives or burrs, or burning oﬀ the lesion with
lasers. The treated segment of artery may be kept dilated with
meshed “stents” and the patient given antithrombotic/anti-
coagulant agents to prevent short-medium term thrombotic
blockages of the artery after surgery.
Angioplasty, inflating a balloon within a narrowed artery
to crush the plaque and open up the lumen, is a widely
used and relatively cheap treatment for lower limb ischaemia,
angina pectoris, and myocardial infarction [7, 12]. It can
be complicated by acute closure, spasm and elastic recoil
(“rebound”), embolism, or thrombosis [4]. Dilating the
angioplasty balloon catheter not only crushes the stenosing
lesion, but also stretches the adventitia and removes the
vessel endothelium, thus allowing rapid platelet and fibrin
deposition. By disrupting the arterial intima and media,
the plaque’s grumous core may be exposed, thus initiating
further clotting responses [12]. The increase in luminal
area after angioplasty is due to plaque reduction, plaque
translocation to distal and proximal areas, and expansion of
the total vessel area, while luminal loss is most likely due to
late recoil [12, 34]. Arteries treated by angioplasty catheters
have been reported to restenose about 30% of the time,
but may this rise to 60–75% in the lower limbs of diabetic
patients [5, 7, 12, 35].
Atherectomy may be used instead of angioplasty, but is
generally used to debulk restenotic stents or other lesions
prior to brachytherapy [14, 36, 37]. The directional coronary
atherectomy catheter shaves pieces of plaque into a metal
cylinder, and is suitable for removing eccentric lesions [4].
Immediate lumen enlargement after atherectomy is due to
plaque removal, not vessel enlargement [38], and there is a
restenosis rate of 16–31% [36].
Brachytherapy (localised ionising radiation) has been
used to reduce vascular lesion formation after bypass graft-
ing, balloon injury/angioplasty, and stenting [12, 37, 39].
Its success may result from either reducing the number of
proliferating cells (by increasing the number of cells under-
going apoptosis), or by reducing fibrosis and preventing
negative remodelling [3, 12, 40]. Treated vessels are known
to have incomplete healing, due to a lack of endothelial
coverage, persistent fibrin deposition, and inflammatory cell
infiltration [12, 18].
Lasers debulk the vein graft or artery wall without distor-
tion. Hot-tip lasers (such as the argon laser probe) achieve
tissue ablation by thermal eﬀects and can burn through
occlusive plaques, but they also result in extensive thermal
tissue damage, vasospasm, and thrombus. Cold pulse lasers
disrupt chemical bonds by using short, high-intensity bursts
of light which promote coagulation and thermal degradation
of the vessel wall [41]. The holmium laser has been found
to be more eﬀective in treating thrombus-containing lesions
than the excimer laser, while the latter may play a role in
treating in-stent restenosis or stenosed vein grafts [42–44].
Stents are meshed scaﬀolds that are inserted into the
lumen of the vessel after removal of the plaque by other
methods (usually angioplasty). Some stents, however, are
placed around the outside of the graft, as an external,
supporting sheath [17, 45]. Lesions treated with internal
stents have a reduced incidence of restenosis (compared
with angioplasty alone) in large arteries with short lesions
[46, 47], but require a longer hospital stay with the possibility
ISRN Vascular Medicine 3
Vessel occlusion
(atherosclerotic plaque)
Surgical treatment
(eg angioplasty, 
stent placement, 
bypass surgery)
Diet
Lipid accumulation
Leukocyte adherence
Cytokine production
Genetic factors
Environmental factors
EC dysfunction
Vascular injury
Restenosis and vein graft disease
Matrix SMC Remodelling Inflammation (Recoil) Thrombosis
synthesis proliferation
EC loss
/dysfunction
Figure 1: Causes and contributors to atherosclerosis, restenosis, and vein graft disease. Surgical treatment in arteries blocked by
atherosclerotic plaque may result in restenosis or vein graft disease, caused by endothelial cell (EC) loss or dysfunction, neointimal formation
(smoothmuscle cell (SMC) proliferation and extracellular matrix synthesis), inflammation, thrombus incorporation into the vessel wall, and
vascular remodelling (recoil, medial, and/or adventitial growth).
of more vascular complications that may not be amenable to
emergency surgical correction [46, 48]. As fibrin deposition
often occurs on stents [12, 49, 50], their use requires long-
term antithrombotic therapies. Restenosis in stented vessels
is associated with the use of multiple stents, degree of
occlusion, degree of thrombosis, type of stent, polymer
type and composition, excessive stent length, long stenosis
length, and the health of the patient [51]. Up to 60%
of patients develop restenosis after stenting, with diabetic
patients having the higher rates [5]. Restenosis may occur
as a diﬀuse neointimal hyperplasia, as discrete lesions within
the body of the stent or as margin restenosis (possibly due to
displacement of the plaque distally and proximally) [49, 52].
The arteries which develop restenosis may not be treatable
by standard surgical therapy [48], but some may respond to
in-stent treatment using lasers, angioplasty, or brachytherapy
[12, 53]. This is not always a successful angioplasty to treat
in-stent restenosis results in repeat restenosis in 50% of cases
[12, 54].
1.2. What Are Restenosis and Vein Graft Disease? Restenosis
is an exaggerated response of apparently normal arteries
to the typical acute response to injury and is considered
the “Achilles heel” of surgical treatment for atherosclerosis.
The blockages caused by restenosis and vein graft disease
continue to develop with time and are due to a number
of processes including intimal hyperplasia (neointimal for-
mation), recoil, vessel remodelling, persistent inflammation,
fibrin deposition, and/or thrombotic occlusion (Figure 1).
Neointimal formation (SMC proliferation, migration,
and matrix synthesis) in restenotic lesions forms faster than
in the atherosclerotic plaque and is a direct result of the
surgical unblocking of the artery [55, 56], with the degree
of vascular injury at least partly determining the occurrence
or the rate of growth of the blockage [13, 57]. Neointimal
proliferation is not always present in restenotic lesions,
although matrix synthesis usually occurs [16, 18, 58]. When
present, the overall proliferation rate is <4%, although focal
hotspots of proliferating cells may occur [16, 55, 59]. The
collagenousmatrix in restenotic plaques is not well organised
and is less compact than in primary plaque. It is enriched
in the proteins biglycan, perlecan, hyaluronan, and versican
[16, 58, 60, 61]. Many of the cells in the restenotic lesions
resemble myofibroblasts or “synthetic-state” SMC [62, 63].
There are also macrophages present [11, 16], and their
existence in large numbers is strongly associated with the
development of restenosis [14].
Endothelial cell removal or damage during the procedure
exposes the arterial matrix to blood components, triggering
platelet adherence and aggregation, fibrin formation and
thrombosis [13, 15], and influencing the degree of restenosis
experienced [9]. As angioplasty and other surgical treatments
always result in some degree of endothelial cell loss and
thrombosis, reducing the area of mural thrombus may play
a role in minimising restenosis or vein graft disease [6, 9].
It is now evident that patients with luminal thrombus prior
to angioplasty or stenting have a higher risk of restenosis
than those without thrombus [64, 65]. The thrombus
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acts as a scaﬀold and a reservoir of factors produced
by platelets, macrophages and even the enzymes of the
coagulation cascade. These factors promote SMC migration,
proliferation, and matrix production. This, in combination
with remodelling mediated by adventitial fibroblasts, leads to
restenosis.
Blockages may also be caused by constrictive remodelling
[12, 66, 67]. This restructuring of the artery or vein graft
relies on the action of matrix proteases to breakdown
the extracellular matrix [28, 68–70], and this in turn is
influenced by changes in blood flow [66, 67]. Restenosis
can occur when the remodelling reduces the vessel diameter,
when remodelling does not occur, or when the amount
of expansive remodelling is insuﬃcient to compensate for
lesion development [66]. Animal models of stenosis have
shown that both vascular remodelling and neointimal hyper-
plasia determine the final luminal area [57, 71, 72]. The use
of stents reduces the contribution of recoil and remodelling
to restenosis, but appears to increase the contributions of
inflammation and thrombosis.
While it would be convenient to define treated vessels
as “restenotic” or “nonrestenotic” (or with or without vein
graft disease), the response to surgical treatment is not “all
or nothing,” but varies over the entire spectrum [12]. There
are a number of techniques designed to detect the degree
of vessel narrowing after treatment (with varying degrees of
accuracy), but another problem in comparing antirestenotic
treatments lies in the timing of detection and ambiguity
in the definition of restenosis. Clinical restenosis is usually
measured between 3–12 months after treatment, although
some groups have examined arteries as early as 1 month
and as late as 29 months after treatment. Restenosis has
been characterised as a return to ≥70% stenosis and loss
of ≥50% of initial gain; the loss of ≥0.7mm of the vessel
diameter; ≥50% stenosis; loss of 50% of initial gain; 50–75%
stenosis; % loss of initial gain; change from <50% to ≥50%
stenosis; ≥50% stenosis and >50% of initial gain or >20%
luminal diameter; or the recurrence of clinical symptoms or
adverse events. Binary stenosis divides the cohort of patients
(or blockages) into those with <50% stenosis and those with
≥50% stenosis (regardless of initial gain) [5, 8, 14, 21, 22,
46, 53, 73–88]. Vein graft disease is usually measured as
% stenosis. These diﬀerences in how, what and when the
measurement is taken can make decisions as to the suit-
ability of a treatment, or comparisons between treatments
diﬃcult to determine, particularly as restenosis and vein
graft disease do not stop developing (after an arbitrary time
point).
2. Treatment Development and Translation
Many diﬀerent animal models have been created to inves-
tigate treatments to prevent vein graft failure, lack of reen-
dothelialization after surgery, thrombus formation, neointi-
mal formation, restenosis, and vulnerable plaque behaviour.
While many therapies have successfully reduced experimen-
tal neointimal formation, restenosis, and vein graft disease,
they are often less successful when tested clinically. This may
be due to the following potential limitations:
(a) diﬀerent endpoints were studied—in animal studies,
diﬀerences between treatments in neointimal area are
usually measured after termination, using histology
and morphometry. However, many diﬀerences found
in animal models would not have been detectable
if measured using testing modalities or definitions
of restenosis used clinically [9, 12, 20, 89]. Using
alternative or multiple endpoints may have prevented
less profound or marginal therapies progressing to
clinical trials;
(b) interspecies diﬀerences—models in rodents (frequen-
tly used to model neointimal formation/vein engraft-
ment/vulnerable plaque [90–93]) may be of limited
use in predicting the clinical eﬃcacy of a treatment.
The use of multiple species may eliminate less
appropriate therapies from progressing to the clinic;
(c) diﬀerences in the response of an artery to injury—
arteries from anatomically diﬀerent locations in the
same animals, arteries of diﬀerent sizes in the same
animal, and arteries of the same size in diﬀerent
species may all have diﬀerent responses to injury
[10, 67, 94, 95]. In addition, for convenience and
for ethical reasons, some animal models examine the
response of easily accessible arteries that may not be
a problem clinically;
(d) unsuitable model—animal models, of course, are
designed to mimic the target disease in a timely
fashion. However, most animal models of restenosis
involve the manipulation of arteries that are ini-
tially free of atherosclerosis to form a neointimal
thickening. These models do not allow for the
multiple process that contribute to the initiation and
progression of restenosis, vein graft disease, and the
atherosclerotic plaque [10] (Figure 1). However, they
may model aspects of the diseases. For example,
lesions formed in the aortae of rabbits after fat
feeding are good model of fatty streak formation (but
not of atherosclerotic plaque formation). Similarly,
the neointimal thickening that forms after balloon
injury of the rat or rabbit carotid artery is a good
model of early in-stent stenosis [20, 96]. Dogs have
hypercoagulable blood [92], and thus provide a
good model for testing therapies that limit thrombus
formation. A combination of insults or models may
be necessary [20, 97];
(e) premature end of treatment—many trials of antires-
tenotic agents, particularly in small animals, end at
2-3 weeks after surgery, while studies in the pig often
end at 4 weeks. However, it has been shown that
“catch-up” may occur, that is, the neointima contin-
ues to develop after that time (as it does clinically)
until there is no longer a diﬀerence between the
agent and the control [95, 98]. Although it may add
to the expense and the “ethical burden” of a study,
continuing the experiments for a significantly longer
period may a better test of the treatment;
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(f) the wrong response is targeted—in animals, drugs
are often tested for their ability to prevent neoin-
timal formation, whereas in clinical trials they are
usually tested for their ability to regress established
disease. In addition, while much of the restenotic
plaque consists of extracellular matrix, many of the
antirestenotic treatments are focused on reducing
SMC proliferation. Alternative targets may be the
extracellular matrix itself, the blood products that are
incorporated into the plaque, thrombus formation,
inflammation, the endothelium, or preventing SMC
phenotypic change or long-term vessel remodelling.
Limiting a therapy to only one of these many aspects
(such as SMC proliferation) not be eﬀective when
observed clinically [18];
(g) reductions in the dose of the agent delivered—doses
of drugs found most eﬀective in animal models are
often reduced in the clinic, sometimes by as much
as 70-fold [99]. This may be due to noncompliance,
but it may also be because symptoms that cannot be
detected in animals (such as nausea) and alterations
in body functions permissible in animalmodels (such
as changes in blood pressure) are not tolerated in
humans [99];
(h) the duration of exposure to the agent given clinically
may have been outside the window of interventional
opportunity established in the animal studies. After
an initial critical time point, the events of resteno-
sis occur over an extended time period—probably
weeks, possibly months. Thus, the delivery system
must be in place and active soon after (or even before)
surgery, must be able to deliver the activated form
of the chemical of interest for extended periods of
time, and must be biologically inert in other ways,
so as not cause an adverse reaction either in the
vessel of interest or in other tissues [99, 100]. The
benefits of several potential antirestenotic agents have
been shown to be dependent on their presence in the
animal before angioplasty, that is, pretreatment with
the drug is necessary to achieve an eﬀect. However,
in an acute clinical case pretreatment with an agent
is not possible and the drug may be administered
after its optimal dosing time [64]. This is particularly
important for those drugs disrupting the early steps
in neointimal development.
It is very possible that many of the diﬀerences in treatment
eﬀectiveness observed between animal models and the
clinic may be eliminated by a more thorough preclinical
examination prior to the therapy being released to clinical
trial. However, there are some diﬀerences (such as duration,
dosing and timing diﬃculties and side eﬀects) that become
apparent only after studying the treatments in clinical trials.
One way of preventing the complications of many treatments
is to deliver the antirestenotic agents locally rather than
systemically. Thus, systemic eﬀects, as well as the incidence
of bleeding and restenosis, should all be minimised.
3. Targeted Delivery Techniques
To successfully reduce the incidence or degree of restenosis,
agents (whether naked or encapsulated, mechanical or drug,
gene or cellular) must be available in a usable form at the
site of interest. There are many ways in which antirestenotic
agents can be locally or site-delivered, including directly via
luminal delivery catheters, in gels or microspheres placed
around the adventitia, or on coated stents, but some of these
techniques may result in greater trauma to the vessel than the
potential benefit of therapy [101]. Agents that interact only
with certain types of cells (such as rapidly proliferating cells
or cells with a particular membrane receptor) or antibodies
linked to agents may also be used [102–107]. The locally
delivered substances result in increased concentrations of the
drug in the place where it is required, leaving the remainder
of the body with much lower levels of the drug. Ideally,
target delivery of the drug should also extend the residence
time of the drug, and may also improve its activity and
bioavailability. These combined actions reduce (or eliminate)
the need for repeated administration of the drug, reduce side
eﬀects (systemic eﬀects and damage to healthy tissue) and
maintain a more uniform delivery of the drug. As there is a
single dose, the cost and length of time in hospital may be
reduced, but there is little opportunity to alter the dose of
drug given.
3.1. Stents. When used in the lumen of vessels, stents are
used as scaﬀolds to hold open arteries after plaque removal,
preventing spasm and remodelling, and are thus ideal as a
local delivery medium. When loaded with antiproliferative
compounds (such as paclitaxel or rapamycin) drug-eluting
stents have significantly reduced the restenosis rate to less
than 10% [7, 23, 108, 109]. However, their use is not totally
devoid of problems. Many stents evoke an inflammatory
response and are limited as to the amount of agent that
can be applied to them. This can lead to eventual drug
depletion from the stent [23, 99, 110, 111]. Long-term drug
treatments (such as antithrombotic treatments) are usually
used concurrently with the stents [112]. Despite this, drug-
eluting stents are associated with an increased incidence of
delayed thrombotic events (usually associated with impaired
reendothelialization after stent placement and the end of
antiplatelet therapy or noncompliance with the therapy),
safety issues (e.g., polymer toxicity, bioincompatibility),
increased cost, and the unsuitability of stents for certain
anatomical locations or conditions [7, 23, 50, 111].
3.2. Delivery Catheters. Delivery catheters, like angioplasty
catheters, are inserted into the artery and used to deliver
therapies locally into the vessel wall [23, 99, 113, 114].
Catheters coated with a gel containing the agent and
catheters which inject the agent into the artery wall through
fine needles or a fine spray have been trialled [21, 23, 99],
but are expensive, may result in vascular barotrauma and are
potentially damaging if incorrectly placed [99, 115]. Another
form of delivery catheter, the double-balloon catheter, stops
the flow of blood through the vessel under study by inflating
balloons at either end of the catheter. The agent is introduced
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into the cavity and allowed to passively infuse into the
artery wall. This involves long dwell times resulting in vessel
ischaemia and is not suitable for many arteries, including
coronary vessels [99, 115]. Most catheters have variable
delivery eﬃciencies, with much of the infused material
subject to washout (with subsequent systemic exposure)
[18, 99].
3.3. Perivascular Delivery. During perivascular delivery, the
therapy is deposited around the adventitia of the artery or
engrafted vein. The active agent leaches from the delivery
vehicle or carrier and diﬀuses into the vessel wall, aided by
the vasa vasorum (if intact), until there is an even distribution
of the drug throughout the vessel [116]. Thus, there is
an increase in local drug concentration without significant
systemic eﬀects [117]. There have been several preclinical
studies designed to extend the dwell time around the vessel,
including encapsulation of the drug in microspheres, or
holding the treatment in place using gels made of fibrin or
pluronic material [116, 118–121]. An alternative solution
may be to expose the vessel to the cell that makes the
treatment, rather than present the drug directly to the vessel
[122, 123]. External stents (or scaﬀolds) placed around vein
grafts may also be used as a form of local drug delivery,
restricting the treatment to the adventitial area inside the
stent. However, vessels that have been treated transluminally
(e.g., angioplasty, internal stent placement) are not suited to
perivascular delivery techniques.
3.4. Ex Vivo Delivery to Vein Grafts. Vein grafts lend them-
selves particularly to treatment ex vivo, with treatment
occurring after the vein has been harvested, while the arterial
insertion site is being prepared. Luminal or adventitial
administration of antithrombotic or antirestenotic products
spare the cut edges of the vessel and can be performed
without delaying the surgical procedure [124, 125]. Drugs
may be administered directly, but gene or cell seeding
treatments are becoming more common [40, 124–127].
3.5. Antibody- or Peptide-Targeted Therapies. Targeted deliv-
ery of antirestenotic drugs has also been achieved by utilising
a technique similar to Nobel Prize winner Paul Ehrlich’s
“magic bullet” for the treatment of cancer [128]. Drug-linked
antibodies are a form of noninvasive treatment that delivers
the drug of choice directly to the target tissue. If the antibody
is suﬃciently specific, only a low concentration of the agent
bound to the antibody need be administered. The chance of
long-term deleterious eﬀects is very low.
For example, antifibrin antibodies can target clots specif-
ically. After surgical disruption of the atherosclerotic plaque
or placement of a vein graft, factors in the artery wall (such
as collagen, phospholipid, or the grumous core) are exposed,
and provide sites for fibrin formation and the recruitment
of more platelets [103, 129]. This fibrin is deposited onto
the injured artery surface within 10 minutes of injury,
where it can remain for at least 24 weeks [130]. Antibodies
recognising fibrin have been conjugated to a number of
potential therapies, to target the drugs to the site of fibrin
formation, that is, the site of injury. Various antibody-drug
therapies have been shown to reduce thrombosis, neointimal
formation and vessel remodelling, as well as improving
reendothelialization in the vessel [102, 104–107, 131].
Other treatments targeting the thrombotic system have
also been employed to deliver antithrombotic drugs.
Arginine-glycine-aspartic (RGD) peptides target the inte-
grin GPIIb-IIIa receptors expressed on activated platelets,
and have been used to direct liposome nanoparticles for
treatment delivery [132]. Similarly, the surface of perfluo-
rocarbon nanoparticles has been bound to targeting ligands
including tissue factor, collagen and integrins [133–135].
Some growth factors and cytokines are selective for
certain cell types or for cells under specific conditions.
This allows the delivery of toxins or other agents directly
to the cell, so that the cell accepts the conjugate and
then dies or alters its behaviour. Compounds used include
saporin, diphtheria toxin, and pseudomonas toxin linked to
fibroblast growth factor (FGF)-2, epidermal growth factor
(EGF) or transforming growth factor (TGF)-β [99, 112,
136]. FGF-saporin, for example, limits neointimal formation
in injured rat carotid arteries by killing medial SMCs
[99]. In another study, adenoviruses (encoding a tissue
inhibitor of metalloproteinase) were linked with peptides
targeting metalloproteinases (present in increased numbers
in restenotic tissue) to limit neointimal thickening in a rabbit
model [137].
3.6. Gene and Cell-Based Targeted Delivery. There is consid-
erable interest in the use of gene therapy in the treatment of
restenosis and atherosclerosis. One approach is to seed the
vasculature with cells containing the gene for a particular
product. Alternatively, the gene therapy can occur by directly
transforming the cells of the artery wall in situ by infusion
of naked DNA or antisense oligonucleotides or by packaging
the genetic material into liposomes or viruses [99, 123, 125,
138, 139]. This may be targeted to the area of interest by the
use of catheters, microbubbles, gene painting, nanoparticles,
or stents to target the lumen or adventitia of the vessel.
However, the agent must be capable of moving into the cell,
where, if successfully integrated, the product is manufactured
and released into the local environment.
Many of the current methods of in vivo gene transfer
are subject to high rates of washout and have a short
exposure time, poor levels of targeting and low transfection
eﬃciency. The proportion of successful transfers varies.
About 1% of cells take up DNA liposome or virus while
there is a transfection rate of 10–70% through the use
of adenoviruses [99, 112, 115]. Gene vector delivered by
catheters during angioplasty can have a 5% transfection
eﬃciency, intramuscular injection a 0.1–1% eﬃciency (with
adenoviral vectors), and periadventitial delivery a 0.1%
eﬃciency [89, 140, 141].
3.7. The Use of Nanoparticles in Targeted Drug/Gene Delivery.
One way to improve the delivery eﬃciency of drugs or genes
is to enclose or attach them to nanoparticles. Nanoparticles
are 1–100 nm in size, with a large surface area, and often have
magnetic and fluorescent properties [131, 134, 135, 142].
After incorporation into nanoparticles, the therapies should
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Figure 2: Sites of action of antirestenotic drugs. After surgical treatment for atherosclerosis, a number of drugs with antirestenotic potential
may be administered to retard or eliminate the development of restenosis or vein graft disease. These include anticoagulants, antiplatelet
and antithrombotic drugs, anti-inflammatory agents, antiproliferative and cytostatic drugs, lipid-lowering drugs, and antioxidants. ACE-
I: angiotensin-converting enzyme inhibitor; HSPG: heparan sulphate proteoglycan; MMP: matrix metalloproteinase; mTOR: mammalian
target of rapamycin; NO: nitric oxide; SMC: smooth muscle cell; tPA: tissue plasminogen activator; uPA: urokinase plasminogen activator.
be better protected from degradation, making them available
for longer periods and enhancing their therapeutic eﬀects.
This is a particular advantage for hydrophilic drugs, which
are otherwise readily lost.
A number of diﬀerent types of nanoparticles have been
examined for their potential in antirestenotic therapies.
These include organic liposomes, polymers, and perfluoro-
carbon nanoparticles and inorganic nanoparticles such as
layered double hydroxides (LDHs), magnetic nanoparticles,
and titanium oxide (TiO2). For example, liposomes incorpo-
rating antirestenotic drugs have been used to coat metallic
stents and shown to function as a drug carrier in small
animals [143–145], while LDH has been used to increase
the amount of drug delivered in fibrin/antibody-targeted
therapy [131].
4. Targeted Therapies
Many drugs have been tested in vitro and in animal
models for their potential in the prevention or reduction
of restenosis and vein graft disease. Most treatments are
directed at reducing one or more of acute thrombosis; vessel
recoil; remodelling; neointimal formation (including SMC
phenotypic change, migration and proliferation, and extra-
cellular matrix formation); inflammation; incomplete reen-
dothelialization; altered endothelial cell behaviour; delayed
thrombosis (as outlined in Figure 1).
Antirestenotic drugs and therapies can be categorised
into several groups based on their original use and/or
targets (Figure 2). These include anticoagulatory, antithrom-
botic and antiplatelet agents (e.g., heparin, ridogrel);
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anti-inflammatory agents (e.g., dexamethasone, tranilast);
antiproliferative drugs and growth factor antagonists (e.g.,
trapidil, tyrphostin, angiotensin-converting enzyme (ACE)
inhibitors); cytostatic drugs (e.g., paclitaxel, rapamycin);
lipid-lowering agents (e.g., statins); and antioxidants (e.g.,
probucol, resveratrol) [10, 18, 115, 146–151].
4.1. Antithrombotic and Antiplatelet Agents. When given
after acute events, oral anticoagulants/antithrombotics can
reduce the incidence of reinfarction or stroke, and so
have become a standard treatment after acute myocardial
infarction. Anticoagulants, as antirestenotic agents, may
limit the amount of thrombus incorporated into the artery
wall, thus minimising bulk in the stenosis and removing
a potential source of factors that stimulate SMC migration
and proliferation. Some, like the heparins, may also act as a
replacement for lost extracellular matrix or act more directly
as an antiproliferative agent. Platelets play a significant role in
restenosis by releasing agents that may act as potent mitogens
of SMC migration and proliferation, and by increasing the
degree of thrombus buildup on the artery wall. Thrombin
inhibitors act by preventing the formation of thrombin
or interfering with thrombin’s properties, thus preventing
thrombus formation and platelet deposition in, or on, the
artery wall.
The anticoagulants heparin and lowmolecular weight hep-
arin (LMWH) inhibit proliferation and migration of arterial
SMCs in vitro and in vivo if given immediately after injury at
a suitable tissue concentration [19, 117, 118, 152, 153]. Data
concerning clinical restenosis rates after heparin treatments
have been conflicting, but this may be due to the dose of
heparin given in many of these trials being considerably
lower than those shown to be eﬀective in animals [21, 75,
154]. Heparin has a short half-life, and it may be the timing
of intervals between heparin doses that are critical in the
prevention of restenosis [19, 115]. Rats given heparin at
time intervals comparable to those given in clinical trials
had increased hyperplasia after balloon injury compared
with those given no heparin. When heparin was given
continuously, however, both intimal hyperplasia and intimal
proliferation were significantly reduced [19]. Unfortunately,
clinical treatment with heparin given systemically can result
in bleeding complications at other sites unless low doses
are given [155]. To prevent this complication, it is best to
administer heparin and related compounds as a single dose,
locally delivered therapy.
It is not necessary for heparins to enter the cell to exert
their eﬀect. If administered at suﬃcient concentration and
at the correct time, they remain eﬀective in reducing SMC
proliferation even when bound to extracellular matrix [115].
This may explain why stents covalently coated with heparin
(“Hepamed”Wiktor stents) placed in the pig coronary artery
were found to be eﬀective in limiting SMC proliferation and
restenosis [153], even though it is unlikely that all of the
heparin was released from the polyethylene imine polymer
on the stent. This sort of stent will extend the active life
of the heparin (for at least 4 months) as well as keeping
it local to the tissue being treated [40]. Other researchers,
using a similarmodel, failed to find a diﬀerence in neointimal
formation between the control (bare metal stent) and the
heparin-eluting stents. This is probably because the dose
of heparin released from the cellulose ester polymer on
the stent was too low to be eﬀective (<0.001U/hr released
over the first week) [156]. A stent coated with 3.2U of
ionically bound heparin (which is readily released from
the stent so it can be taken up by cells or available to
neutralise thrombin [40]) reduced proliferation, thrombus
formation and neointimal area in a similar pig model
[157]. A clinical trial of the “Hepamed” heparin-eluting
stent found that it was eﬀective in reducing thrombotic
events [158]. In the Benestent II study, Palmar-Schatz-style
heparin-eluting stents were eﬀective in reducing the degree of
restenosis and number of clinical events 12 months after the
procedure [159], but a trial using the low dose Jostent (<1U
heparin/stent) was inconclusive [160]. In the successful trials,
the restenosis rate was reduced from 31% to 7–16% [159,
160]; it would be interesting to ascertain what the rate would
be if the treatment was optimised. It is evident that the dose
of heparin bound to the stent and the way the heparin is
bound to the stent (e.g., noneluting (covalent) or diﬀusible
(ionic)) are critical to the success of treatment with heparin.
Unfortunately, it is all too easy to combine the results of these
heparin site-delivery studies, label them as “conflicting” and
stop research in this area.
While LMWH can inhibit cultured human SMC prolif-
eration by 20–40% [152], this does not prevent phenotypic
change or proliferation of rabbit SMC [119]. Eﬀects in vivo
are also variable [119, 161], but LMWH at 10 times the
clinical dose was able to maintain lumen diameter in rabbit
models (arterial injury with or without atherosclerotic diet)
by reducing the incidence of early SMC proliferation [161,
162]. Local delivery of LMWH after vascular injury using
a porous balloon catheter was associated with improved
reendothelialization, and elevated early and reduced late
SMC proliferation, resulting in reduced neointimal forma-
tion compared with control rabbits [162, 163]. Clinically,
systemic high dose LMWHs (with or without pretreatment)
may improve patency in peripheral bypass grafts [39], but
may not prevent restenosis [74, 78, 80, 81]. Further clinical
studies of locally delivered LMWH pinned in place with
a stent after drug administration showed a decreased the
degree of restenosis [82], but a study on “unsecured” LMWH
delivered in a similar manner found that the drug was not
eﬀective [164]. It may be that LMWH needs to be held in
place in order to act as an antirestenotic agent.
In order to keep the anticoagulant in position in at
the site of surgery (the site of fibrin formation [130]), an
antibody that recognises cross-linked fibrin D-dimer was
conjugated to heparin or LMWH and these conjugates
injected i.v. into rabbits after balloon injury. Animals
given either conjugate had reduced neointimal formation,
decreased luminal narrowing and positive remodelling, with
more endothelial cells and fewer neointimal cells [106]. More
recently, LMWH was intercalated into LDH nanoparticles
prior to conjugation to the same antibody, to increase the
dose delivered and improve the therapeutic eﬀectiveness of
the LMWH [131]. Enclosure within the LDH improved
the bioavailability of the LMWH and protected it from
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degradation within the cell, resulting in reduced SMC prolif-
eration andmigration [165, 166]. Conjugating LMWH-LDH
to the antibody did not interfere with the antibody’s ability
to bind to cross-linked fibrin or in the ability of vascular cells
to internalise the conjugate. Injured arteries exposed to the
nanoparticle conjugate had decreased neointimal formation
and increased patency compared with those given control
agents [131].
Hirudin prevents thrombin-catalysed activation of coag-
ulation factors, fibrinogen cleavage, and platelet aggregation,
thus limiting thrombus formation [167]. It is eﬀective
in reducing neointimal area and tissue factor expression
in balloon-injured hypercholesterolaemic rabbits [168–170]
but has conflicting results in injured pig arteries [15,
167, 168, 170], probably due to diﬀerences in dosing and
timing regimens. Interestingly, it does not appear to have
an eﬀect on cellular proliferation in vivo [169]. In the
clinical HELVETICA study, hirudin (given systemically) was
found to cause a reduction in early cardiac events, but did
not prevent restenosis or improve long-term survival [77].
However, the dosage used in this study was 5-fold less than
those used in animal experiments. An antibody-directed
fibrin peptide-targeted form of Xa-activated hirudin has
been made. This conjugate preferentially targeted clots and
activated hirudin at the site of the thrombi. It also prevented
thrombus formation on synthetic grafts in primates [103,
129]. Hirudin-coated stents in pig arteries were found to
reduce thrombus formation and neointimal area [110],
while stents coated with a hirudin-iloprost combination also
reduced restenosis in pig and sheep arteries. However, over
half of the hirudin was released within the first 24 hours,
suggesting that the positive eﬀect was largely due to the
presence of iloprost, which eluted slowly from the stent
polymer [171].
Elements of the fibrinolytic pathway have been utilised as
antithrombotic agents, but their systemic use at therapeutic
doses can lead to uncontrolled bleeding or rebound throm-
bosis [6, 172]. To eliminate these complications, a number
of site-delivered or targeted therapies have been developed.
“Synthetic-state” SMCs are known to have impaired tissue
plasminogen activator (tPA) production and SMCs from
atherosclerotic plaques a reduced capacity for initiating
fibrinolysis [173], possibly because of complexing of the
enzymewith the increased amounts of plasminogen activator
inhibitor (PAI)-1 present in plaque [174]. Vein grafts have an
early loss of tPA-associated fibrinolytic activity [175], with
failed grafts having less tPA than viable grafts [176]. Targeted
delivery of urokinase plasminogen activator (uPA) to arterial
thrombi using coated catheters and tPA delivery by a
microporous catheter as a bailout intervention for peripheral
artery disease and to treat thrombus in coronary arteries have
been investigated [23]. Antibody conjugates have also been
used to target-deliver tPA to the site of thrombus formation
[104]. Luminal exposure of pig vein grafts to tPA enzyme was
found to be suﬃcient to improve the thrombolytic activity
of the grafts [126]. In other experiments in pigs, tPA gene
therapy was delivered locally to vein grafts ex vivo, to replace
the tPA lost from endothelial cells and their underlying
SMC in the graft, thus limiting acute thrombus formation
following implantation of the graft into pig carotid arteries
[125]. Blood flow in the transduced grafts was higher than in
control grafts. This is an important observation, as a high
initial blood flow in the graft is known to be critical in
limiting thrombosis and graft failure [177]. Fewer platelet-
rich thrombi (measured as cyclic flow reductions (CFRs))
formed in the tPA-transduced grafts, and any CFRs that did
form were smaller and resolved faster than those formed in
grafts given a control virus [125]. Reduction of the thrombus
load in vein grafts should lead to a reduction in neointimal
formation and vein graft disease [6], or delay the onset
of these pathologies. However, the dose of tPA and the
vessel involved are critical, as excess tPA may result in early
extracellular matrix degradation and increased neointimal
formation [178].
Agents that block the platelet GPIIb/IIIa receptor, the
most abundant glycoprotein on the platelet surface, inhibit
the binding of fibrinogen to platelets and hence platelet
aggregation [179]. These agents include aspirin, ticlopidine,
roxifiban, and clopidogrel. When given systemically, they can
reduce the incidence of thrombosis in animal models [180],
but do not always reduce neointimal formation [181]. When
given clinically they reduce the number of cardiac events
[182], but trials suggest that they are not eﬀective in reducing
restenosis [183]. Cessation of clopidogrel therapy is associ-
ated with late stent thrombosis [23]. Systemic administration
of abciximab, a manufactured antibody against the GP
IIb/IIIa receptor, also reduces clinical events (if maintained
for a suﬃcient time [184, 185]), but is not associated with
improved outcome after stenting or a reduction in restenosis
rates [186]. Abciximab does, however, have a positive eﬀect
in patients with diabetes [151]. When delivered locally using
a spiral delivery catheter, abcximab reduced the thrombotic
burden in stenosed vein grafts [187]. This treatment may
also be of benefit in the treatment of thrombosed coronary
arteries [23]. Preclinical experiments on stent-delivered
abciximab in pigs indicated that neointimal formation and
inflammation levels after this treatment were comparable
to vessels given paclitaxel- or rapamycin-eluting stents (see
below) [188].
Thromboxane A2 (TXA2) is a potent vasoconstrictor,
and is produced by platelets during signal transduction
after activation of the platelet receptor GP IIb/IIIa [184].
TXA2 synthetase inhibitors such as ridogrel are eﬀective in
preventing platelet aggregation in balloon deendothelialised
rabbit arteries [189] and human arteries after angioplasty
[190] and reduce the incidence of clinical restenosis [191].
Ridogrel also increases vasodilatation. Combined systemic
ridogrel/ketanserin or ridogrel/ketanserin/clopidogrel treat-
ment prevented platelet aggregation (as CFRs) in stenosed
or balloon-injured coronary arteries in a dog model and
reduced neointimal formation [192, 193]. While ridogrel has
been successfully delivered into the artery wall of dogs via
a microporous balloon, it resulted in only transient high
vessel wall concentrations of the chemical [194] and was
found to be ineﬀective in reducing thrombus and neointimal
formation.
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Iloprost is a prostacyclin analog with vasodilatory and
antithrombotic eﬀects, which can reduce neointimal for-
mation [39]. When given systemically, it resulted in early
improvement in flow to artificial venous replacement grafts,
but this benefit was not sustained [39]. However, use of a
spiral delivery catheter to facilitate gene transfer of prosta-
cyclin synthase resulted in reduced in-stent restenosis in a
rabbit model, with improved endothelialisation compared
with vessels given a control virus after stenting [195].
Cilostazol is a specific inhibitor of cAMP phospho-
diesterase III, an enzyme that breaks down cAMP and
therefore inhibits platelet aggregation, thrombus formation
and SMCmigration and proliferation. It can also increase the
reendothelialization of the vessel and improve vasodilatation
(by increasing nitric oxide levels) [196, 197]. It can limit the
development of clinical restenosis when given systemically
[39, 198, 199], particularly when coadministered with the
antioxidant probucol [200]. When used in pigs, cilostazol-
eluting stents were eﬀective in reducing neointimal area
compared with bare metal stents [197], while cilostazol-rich
pluronic gels were able to reduce neointimal formation in
injured rat arteries [201].
4.2. Anti-Inflammatory Agents. Inflammation is a major
contributor to restenosis, and it has been suggested that
the severity of the response to the surgical treatment is
not due to the presence of SMC, but due to macrophage
content in the lesion [14]. Anti-inflammatory agents inhibit
the accumulation and activation of cells at the site of
injury, leading to a reduction in growth factor release, cell
recruitment and low density lipoprotein absorption and
oxidation, thus limiting the degree of neointimal formation
[146].
Dexamethasone is an anti-inflammatory steroid that
acts by decreasing toll-like receptor signalling (and thus
chemokine production), and reducing arachidonic acid
metabolism, prostaglandin production and leukocyte rec-
ruitment [202, 203]. Targeted delivery techniques may
be better than systemic use, as dexamethasone has been
associated with the development of latent diabetes, immuno-
suppression and drug dependency. While locally delivered
nanoparticle-encapsulated dexamethasone or periadventitial
treatment with silicone polymer-implanted dexamethasone
limited neointimal formation in the balloon-injured rat
artery [204], high concentrations of stent-bound dexam-
ethasone, while well tolerated in the artery wall, resulted
in only a limited reduction in neointimal formation in
a pig model [99]. However, stents coated in combined
dexamethasone and rapamycin were eﬀective in preventing
in-stent restenosis in pig and dog models [205]. Clinical
trials of dexamethasone-bound stents have commenced,
with favourable early results [100, 206]. Further trials are
underway using a microinfusion catheter to site-deliver
dexamethasone (as an antirestenotic agent) to the adventitia
via the lumen (http://www.mercatormed.com/).
Liposomes are vesicles composed of lipid bilayers and
are readily phagocytosed by inflammatory cells. Liposome-
mediated delivery of bisphosphonates (alendronate or clo-
dronate) was able to reduce neointimal formation and
the infiltration and proliferation of inflammatory cells
(macrophages and monocytes) in balloon injured or
stented rabbit arteries [143, 144]. Gallium and gadolinium
nanosuspensions of alendronate were similarly able to limit
neointimal formation in injured rat arteries [207].
Tranilast, an anti-allergic and anti-inflammatory drug,
inhibits the release of growth factors (particularly TGF-β)
after experimental neointimal injury, stent implantation or
transplantation, limiting neointimal formation. It does this
by preventing leukocyte accumulation, SMC migration and
proliferation, and collagen and glycosaminoglycan synthesis
and accumulation [208–210]. It also reduces prostaglandin
and increases nitric oxide production. Small early studies
indicated that tranilast reduced the incidence of clinical
restenosis [10, 86, 211], but the much larger PRESTO
study indicated that while tranilast reduced the incidence
of myocardial infarction, it had no eﬀect on the incidence
of restenosis. Treatment was stopped prematurely due to
adverse side eﬀects [85]. This drug appears to be a prime
candidate for targeted local delivery, as it can influence many
of the factors that contribute to the initiation of the restenotic
response.
4.3. Antiproliferative and Antimigrating Agents. SMCs res-
pond to injury by migrating, proliferating, and producing
extracellular matrix, and this response is often stimulated
by growth factors released during injury. These responses
occur following change from a “contractile” to a “synthetic”
phenotype [26, 27, 35]. If this response to injury can be
reduced or eliminated then the restenotic response may be
minimised [212]. However, treatments that alter this SMC
response should not also decrease the reendothelialization of
the vessel.
One major growth factor upregulated in restenotic
plaques is TGF-β, while others (like platelet-derived growth
factor (PDGF)) are also know to promote SMC proliferation
and phenotypic change [16, 213]. These growth factors
also stimulate SMC production of the inflammatory matrix
proteins hyaluronan and versican [116]. Agents that prevent
the stimulation of SMC by growth factors, such as trapidil (an
antiplatelet drug that also antagonists PDGF [214])minimise
proliferation and migration in animal studies, whether
delivered systemically [214, 215] or locally [216]. Trapidil can
also reduce the rate of clinical restenosis [10, 39, 217]. Locally
delivered antisense TGF-β1, has been administered to arteries
via pluronic gels applied to the arterial adventitia, and to vein
grafts using nanoparticles, with a subsequent reduction in
neointimal thickening [116, 218]. Tyrphostin (an inhibitor
of SMC proliferation by reducing growth factor receptor
activity [219]) reduces neointimal formation when applied
locally to the adventitia of injured arteries (in pluronic gel).
Local delivery of tyrphostin (using the biodegradable organic
nanoparticle polylactic acid) following balloon-injury of rat
carotid arteries or stenting of porcine coronary arteries was
also successful in limiting neointimal formation [142, 220,
221]. These experiments suggest that tyrphostin may be
suitable for use in the delivery of antirestenotic therapy
independent of stent design or type of injury.
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Angiopeptin, a somatostatin analog, is also thought to
inhibit local growth factor activation of SMC. Although
eﬀective in reducing neointimal formation in animal models
[39, 222], it has conflicting clinical eﬀects when given
systemically. Although it reduced the incidence of restenosis
in a preliminary trial, it was not eﬀective as an antirestenotic
agent in a larger trial [148, 149]. However, small trials of
locally delivered angiopeptin (stent-delivered or catheter-
delivered) are more promising [113, 223].
Pluronic gels applied to the arterial adventitia have been
used in animal models to locally deliver ACE inhibitors [214,
224], with a subsequent reduction in neointimal thickening.
This change may be due to improving endothelial cell func-
tion, PAI-1 antigen attenuation (thus reducing thrombosis),
or due to a decrease in matrix metalloproteinase production
and matrix remodelling (thus limiting SMC migration) and
SMC proliferation [225].
All of these treatments are designed to reduce the
number of SMC present, by limiting SMC proliferation.
An alternative approach is to prevent SMC apoptosis, so as
to preserve plaque cap thickness. The local delivery of the
caspase inhibitor ZVAD-fmk by a delivery catheter inhibited
SMC apoptosis and reduced neointimal proliferation with-
out aﬀecting reendothelialization in balloon-injured injured
rabbit arteries [226].
Agents that alter matrix composition or lipid-carrying
capacity are also potential antirestenotic treatments.Heparan
sulphate proteoglycans, present in the immediate environ-
ment of SMC, not only act as low aﬃnity receptors for
growth factors but also influence cell phenotype [27, 119,
227]. When delivered locally in a pluronic gel they were
found to inhibit the formation of the neointima after
injury of rabbit carotid arteries [119]. Heparan sulphate
proteoglycans and extracellular matrix proteins are degraded
by heparanases and metalloproteinases released from vascular
cells. Inhibition of these enzymes has been used successfully
in culture systems and in animal models of changes after
angioplasty, but is not currently suitable for clinical use
[29, 66, 127, 228]. The ability of the extracellular matrix to
store lipid (a pro-restenotic stimulus) can also be altered.
Versican is a major matrix protein in restenotic vessels [16,
58, 61]. Balloon-injured arteries in rabbits fed a variable
(high-fat/normal) diet were seeded with SMC transduced
with versican variant V3. These arteries had less neointimal
formation, and increased resistance to lipid deposition and
inflammation, due to their altered matrix composition
[123].
4.4. Cytostatic and Immunosuppressive Agents. Colchicine
binds to tubulin (inhibiting microtubule polymerisation),
thus preventing cellular proliferation and migration. It can
also inhibit the release of neutrophil-attracting chemokines
and act as an anti-inflammatory agent [229]. Colchicine also
stops the formation of Weibel-Palade bodies in endothelial
cells and decreases the incidence of thrombosis after arterial
injury [230]. In culture colchicine reduces the proliferation
of human restenotic SMC by 60% [152], and (in large doses)
can reduce stenosis in animal models [231]. Colchicine is
quickly cleared after systemic administration, and this may
account for its lack of clinical eﬀect in clinical studies. There
was a high patient drop-out rate in the clinical trials, due to
adverse side eﬀects (despite a reduction in dose from that
found optimal in animal studies) [23, 73, 76, 229, 231].While
an infusion of colchicine via a balloon catheter did not have
a long dwell time in rabbit artery walls, its retention was
improved by containment within microparticles, resulting in
a decrease in neointimal thickening [232].
Paclitaxel (taxol) is an antiproliferative microtubule-
stabilising agent that is toxic to almost all cells [233]. Thus
paclitaxel must be given locally-systemic delivery results in
significant adverse symptoms. Facilitating the passage of
paclitaxel into the artery wall is more diﬃcult than for other
drugs (such as heparin), but once present its hydrophobic
nature means that it is more likely to be retained within
the wall, and to be present in a greater concentration [234].
Rabbits with paclitaxel-eluting stents and rats given paclitaxel
locally via the perivascular route were found to have less
stenosis than control animals. However, the arteries had
incomplete healing of the endothelium, increased numbers
of inflammatory cells, and extensive fibrin and platelet
deposition [233, 235–237]. In pigs, paclitaxel given locally
via an arterial stent or administered locally to vein grafts
or arteriovenous shunts resulted in reduced neointimal
formation in the short term [98, 233, 238], but this benefit
was not seen in longer term experiments due to “catch-up”
neointimal formation [98, 233]. Other means of delivering
paclitaxel have been investigated, including encapsulating it
in multilayered “nanoburrs” that have hooks on their surface
that bind to specific peptides on exposed surfaces. These
paclitaxel-nanoburrs were found to be cytotoxic to SMC in
vitro and preferentially bound to the denuded regions of
balloon-injured arteries in rats [239]. Tissue factor-targeted
paclitaxel nanoparticles were similarly able to limit SMC
proliferation in vitro [133].
Current clinical trials indicate that stents with high doses
of paclitaxel are successful at reducing the incidence of
restenosis from 5–27% to 2–9% [50, 87, 114, 240, 241],
and may also be eﬀective in reducing vein graft disease
[22, 242]. Longer term studies continue to show the benefit
of paclitaxel-eluting stents in the coronary vasculature [109]
(but not the periphery [243]). However, late thrombotic
events are of concern [24, 25, 244, 245]. Clinical studies have
shown the eﬃcacy of paclitaxel-coated balloon catheters in
the prevention of restenosis, and it is possible that this form
of local delivery may be of benefit in peripheral artery disease
[23, 114].
Rapamycin (sirolimus) has been used as an anti-fungal
agent, antibiotic, antitumour agent and immunosuppres-
sant. It prevents production of antibody-producing cells,
delays SMCmigration, and inhibits proliferation in SMCs, T-
and B-lymphocytes, hepatocytes, fibroblasts and endothelial
cells [246–248]. Like paclitaxel, it is lipophilic and minimally
soluble in water. It has diﬃculty entering the artery wall and
passing into the cell, where it needs to be in order to exert its
eﬀect on mammalian target of rapamycin (mTOR) [23]. It
has a positive short-term, high-dose eﬀect in animal models
of arterial injury, but only if the drug is given suﬃciently
early [205, 249, 250]. Animals given rapamycin systemically
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had extensive alterations, even at low doses [251], but the
dosing diﬃculties and systemic changes were overcome by
using local delivery techniques. When bound to stents,
high doses of rapamycin were found eﬀective in limiting
neointimal formation in rabbit iliac arteries [252]. Targeting
of nanoparticle-rapamycin conjugates to αvβ3 in injured
rabbit arteries also limited neointimal formation [135] as
did use of a rapamycin-conjugated antibody that recognises
cross-linked fibrin [107]. Both forms of targeted delivery
resulted in improved reendothelization of the injured vessels,
with reduced neointimal formation [107, 135].
In fat-fed rabbits, vein grafts given rapamycin periad-
ventitially in pluronic gel had fewer proliferating cells and
80% less neointimal formation at 28 days after engraftment
[253]. Similar experiments on mouse vein grafts found that
periadventitial administration of rapamycin in pluronic gel
resulted in less neointimal formation at 1-2 weeks after
engraftment, but the diﬀerences were no longer significant by
4–6 weeks [254]. Pig saphenous veins bathed in rapamycin
before engraftment into the carotid artery had a smaller
neointimal area at 4 weeks, but by 12 weeks there was no
diﬀerence between control and experimental grafts [98].
This “catch-up” may be due low dosing (due to rapamycin’s
low solubility in water) or exhaustion of the drug within
the artery wall. Periadventitial administration of rapamycin-
eluting microbeads to extend the rapamycin therapy was
investigated, but, once again, while the drug was eﬀective
at early time-points, there was catch-up by 12 weeks after
engraftment. Increasing the dose of rapamycin led to local
toxicity, with graft rupture, inhibition of neoangiogenesis
and accelerated neointimal formation [121].
Short to medium term clinical trials of localised delivery
of rapamycin (or rapamycin analogues) via stents have found
that restenosis is minimal and neointimal hyperplasia is
absent for at least 12 months after implantation [83, 84,
88]. However, extensive culture and animal studies have
indicated that rapamycin can delay or prevent the recovery
of the endothelium, and increase fibrin deposition in blood
vessels [205, 255]. In addition, rapamycin immunosuppres-
sion is associated with an elevated incidence of hepatic
artery occlusion after liver transplantation [256]. Thus,
as with paclitaxel-coated stents, there are concerns about
the elevated levels of late arterial thrombosis in patients
given rapamycin-eluting stent [8, 108, 244, 245, 255, 257].
Thrombosis is also of concern in vein graft disease, as
patients whose grafts have been treated with rapamycin-
eluting stents have an increased risk of late death (due to
thrombosis) compared with those given a bare metal stent
[258]. Many of the new developments in drug-eluting stent
therapy are designed to target this problem [100].
4.5. Regulators of LipidMetabolism. Lipids, recruited into the
artery wall from the blood, produce mechanical instability
within the plaque. Once activated, lipids also participate
in creating oxidative stress and stimulate inflammatory
responses [150]. Agents that prevent this aggregation of lipid
in the blood or the artery wall, or reduce the oxidation
of the lipid components, may be of benefit in reducing
the incidence or degree of restenosis. Statins (HMG CoA
reductase inhibitors) are lipid lowering drugs with few side
eﬀects [147, 259]. They prevent SMC phenotypic modula-
tion, inhibit SMC proliferation andmigration and limit SMC
and endothelial cell metalloproteinase production [260–
264]. They also have immunomodulatory eﬀects and reduce
thrombotic risk in patients with cardiovascular disease [264,
265], and can reduce neointimal growth in animal models
[259, 261].
The proportion of clinical events after stroke, angina,
myocardial infarction, or revascularisation is reduced after
statin treatment [79, 266, 267], possibly due to endothelium-
protective and antioxidant eﬀects [264, 268]. In some trials
restenosis rates remained unaltered [269, 270], but other
trials found that statin therapy reduced the incidence of
restenosis [271, 272], possibly by stabilising the plaque and
preventing artery remodelling in response to inflammatory
stimuli or by or reducing the incidence of thrombosis
[263]. Statin therapy also reduces the incidence of in-stent
thrombosis in patients with an inflammatory profile [273].
When used in pigs, stent-delivered cerivastatin was found to
be eﬀective in improving endothelial function and reducing
inflammation and neointimal formation [274].
4.6. Antioxidants. Reactive oxygen species (including super-
oxide, peroxide, and other free radicals) can be produced
by activated leukocytes and after tissue hypoxia (as happens
during vein graft preparation). Dietary antioxidants, such
as vitamin C (ascorbic acid), vitamin E (α-tocopherol),
and β-carotene (provitamin A) can protect again these
reactive oxygen species, by altering the levels of lipoproteins
circulating in the blood and inhibiting pro-thrombotic
oxidative events in plasma and the artery wall [275,
276]. Generally, increased levels of dietary antioxidants are
associated with reduced primary disease risk and reduced
recurrence of cardiovascular events [101, 275, 277]. Their
use can lead to reduced low density lipoprotein (LDL)
formation and oxidation, and reduced LDL deposition in
tissues. The antioxidant probucol acts by preventing SMC
proliferation and suppressing the release of interleukins from
macrophages. It can also reduce SMC metalloproteinase
secretion, reverse cholesterol transport and promote positive
vascular remodelling [200, 278]. Probucol at high doses can
prevent the progression of atherosclerosis in animal models
[279]. When given alone, with dosing commencing 30 days
before clinical angioplasty, probucol significantly reduced
luminal narrowing and the incidence of restenosis, but when
given with vitamin supplements its beneficial eﬀect was
reduced [280] or eliminated [278, 281, 282].
Composite stents coated with resveratrol and quercetin
(polyphenols found abundantly in grapes) were eﬀective
in preventing luminal stenosis and inflammation, while
promoting reendothelialization of the injured rat artery
[283]. This could be a promising additional therapy to
prevent late thrombosis after drug-eluting stent placement.
Another way to protect the vasculature against reactive
oxygen species is by the administration of nitric oxide,
either via gene therapy or directly via nitric oxide donors
[33, 39, 120, 139]. Nitric oxide therapy can inhibit platelet
aggregation and adhesion, limit leukocyte adhesion, induce
ISRN Vascular Medicine 13
SMC apoptosis, and reduce vasoconstriction [284]. While
systemic delivery has not prevented clinical restenosis [39],
local delivery may be more successful. SMC gene therapy of
nitric oxide synthase in injured arteries in rats and adventitial
delivery of a nitric oxide donor to vein grafts in fat-fed
rabbits reduced neointimal formation [120, 149], and this
therapy is now being extended into clinical trials [139].
Ex vivo experiments indicate that nitric oxide-donating
aspirins may be suitable to prevent thrombosis, spasm and
possibly neointimal formation in vein grafts [33, 285]. Vein
grafts have increased superoxide levels upon exposure to
the arterial environment, and this is known to quench
nitric oxide [286]. Catheter or stent-directed gene therapy
with extracellular superoxide dismutase has been shown
to be eﬀective in improving endothelial cell recovery and
preventing in-stent restenosis [138, 287] and should also be
of benefit in vein grafts.
5. Future Developments in Antirestenotic
and Vein Graft Therapies
The discovery and refinement of treatments to prevent
restenosis and vein graft disease is an active area of medical
research. Therapies that require systemic administration
have been found wanting, and this has led to considerable
interest in developing new delivery systems and improving
established targeting techniques. It is also becoming apparent
that antirestenotic agents must not just be locally delivered
to the appropriate site, but also be supported by some kind
of mechanism to hold it in place, whether mechanical as
in stents [23, 82, 100], or physiological, as in the binding
of antibodies to fibrin formed at the angioplasty site [106,
107] or incorporation into the artery wall [123, 288] for a
suﬃcient time.
However, restenosis and vein graft disease are multi-
faceted diseases, and administration of a single drug directed
at a single aspect of treatment may not be eﬀective at
limiting vessel closure [12], particularly if administered for
a short time. It may be necessary to administer a number
of antirestenotic compounds directed against the vari-
ous aspects of restenosis—proliferation, matrix formation,
inflammation, thrombus incorporation, and remodeling
before the problem of restenosis can be avoided. This therapy
may take the form of a “5-in-1” treatment, or multidrug-
loaded nanoparticles, scaﬀolds or antibodies. Alternately, the
delivery a single multi-function drug (possibly held within
nanoparticles) eﬀective against many or all of these features
may be useful in preventing restenosis. An example of such a
drug is tranilast, a drug with antiproliferative, antimigratory,
anti-inflammatory, antimatrix synthesis, provasodilatation,
and proendothelial properties [85, 86, 208, 209]. Cilostazol
is another possible multiaspect candidate, as it too can
influence many of the aspects involved in the development
of restenosis including thrombus formation, SMC migration
and proliferation, reendothelialization of the vessel and
vasodilatation (by increasing nitric oxide levels). Although
systemic cilostazol therapy is relatively well tolerated (com-
pared with tranilast), site delivery of long-term eluted
drug would eliminate patient noncompliance, bleeding (and
rebound) complications, diﬀerences in dosing regimens, and
so forth.
As the degree of neointimal formation and the incidence
of thrombus formation have been linked with endothelial
cell loss [289], a major improvement would be to ensure
that the endothelium within the vessel remains complete
and that the endothelial cells can still perform their proper
function. Future studies should focus on drugs that preserve
or allow rapid recovery of the endothelium, but still prevent
restenosis/vein graft disease. Use of adjunct drug or gene
delivery therapies that are less immunoresponsive—such as
nanoparticles—should also advance antirestenotic therapies,
by extending drug retention times, and improving drug
activity, bioavailability and release profiles.
These target-delivered multiple-drug therapies will not
be easy to design and optimise. Irrespective of which
delivery system is selected, the doses of the drugs and the
separate release kinetics need to be established. These may
be controlled, perhaps, by encapsulation in microspheres or
nanoparticles, or by layering polymers or using biodegrad-
able polymers. In addition, as diﬀerent aspects of restenosis
may need to be targeted, the timing of the release of the drugs
may need to be staggered, perhaps by coating multiple layers
of products together, which may also be useful in preventing
premature exhaustion of the therapy. A combined therapy
should also eliminate the necessity of additional therapies
(such as the taking of antithrombotic agents with drug-
eluting stents), thus eliminating “rebound” thrombosis and
the possibility of noncompliance.
Restenosis and vein graft disease are the “Achilles heel”
of surgical treatments for atherosclerosis. Current targeted
treatments have already considerably reduced the degree and
incidence of restenosis and vein graft disease, and on-going
refinements will further improve these therapies.
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